Reduced Melatonin Levels Linked To Greater Diabetes Risk

Reduced melatonin levels linked to greater diabetes risk

Reduced melatonin levels linked to greater diabetes risk

Tuesday, April 9, 2013. The April 3, 2013 issue of the Journal of the American Medical Association reports a link between decreased levels of the hormone melatonin and a greater risk of developing type 2 diabetes. Melatonin is a sleep-inducing hormone produced by the pineal gland in response to darkness. The hormone has been investigated as a preventive or treatment for several conditions in addition to insomnia, including complications associated with diabetes.

"Melatonin receptors have been found throughout the body in many tissues including pancreatic islet cells, reflecting the widespread effects of melatonin on physiological functions such as energy metabolism and the regulation of body weight," Ciaran McMullan and colleagues at Brigham and Women's Hospital noted in their introduction to the article. "Loss-of-function mutations in the melatonin receptor are associated with insulin resistance and type 2 diabetes. Additionally, in a cross-sectional analysis of persons without diabetes, lower nocturnal melatonin secretion was associated with increased insulin resistance."

The researchers matched 370 women who developed diabetes while enrolled in the Nurses' Health Study with 370 nondiabetic participants. Morning urine samples obtained upon enrollment in 2000 were analyzed for the ratio of 6-sulfoxymelatonin (the major metabolite of melatonin) to creatinine in order to estimate overnight melatonin secretion.

Women with diabetes had a 6-sulfatoxymelatonin to creatinine ratio that was significantly lower than that of the control group. Among those whose ratio was among the lowest of the participants, the adjusted risk of developing diabetes was more than twice that of women whose ratio was among the highest group.

"This is the first time that an independent association has been established between nocturnal melatonin secretion and type 2 diabetes risk," announced Dr McMullan, who is a researcher in the Renal Division and Kidney Clinical Research Institute at BWH. "Hopefully this study will prompt future research to examine what influences a person's melatonin secretion and what is melatonin's role in altering a person's glucose metabolism and risk of diabetes."

"It is interesting to postulate from these data, in combination with prior literature, whether there is a causal role for reduced melatonin secretion in diabetes risk," the authors remark. "Further studies are needed to determine whether increasing melatonin levels (endogenously via prolonged nighttime dark exposure or exogenously via supplementation) can increase insulin sensitivity and decrease the incidence of type 2 diabetes."

What's Hot Highlight

Osteoarthritis risk raised by diabetes

What's Hot

In an article published ahead of print on September 21, 2012 in the journal Diabetes Care, European researchers reveal a significantly increased risk of severe osteoarthritis necessitating arthroplasty (joint surgery) in adults with type 2 diabetes.

The study included 927 men and women between the ages of 40 and 80 years who enrolled in 1990 in the Bruneck cohort, a prospective study of the epidemiology and pathogenesis of cardiovascular, neurologic and musculoskeletal diseases. Physical examinations conducted upon enrollment ascertained the presence of diabetes and other conditions. Sixty-nine participants met the criteria for type 2 diabetes at the beginning of the study. The subjects were evaluated at follow-up visits conducted every five years for a 20 year period.

Over follow-up, arthroplasties for severe hip or knee osteoarthritis were performed in 13 diabetic and 73 nondiabetic subjects, which was equivalent to more than double the adjusted risk of severe arthritis among the diabetic participants. In an additional analysis conducted in 2010, participants with diabetes were also found to have more severe arthritis symptoms and signs of inflammation compared to nondiabetics.

Authors Georg Schett, MD of the University of Erlangen-Nuremberg and his colleagues remark that the metabolic changes involved in obesity rather than damage to the joints caused by greater weight may be responsible for the elevated risk of arthritis observed in those with type 2 diabetes. "To our best knowledge, this is the first time that it was shown that diabetes can be considered as an independent predictor of severe osteoarthritis necessitating joint arthroplasty," they announce. "The link between osteoarthritis and type 2 diabetes suggests that alterations in glucose metabolism directly affect joint integrity independently of body weight and creates room for hope that adequate control of glucose metabolism hampers development of osteoarthritis."

Free Documentary: The War on Health




This new film from award-winning documentary-maker Gary Null delivers irrefutable evidence as to why we have so few cures for killer diseases . . . and how pharmaceutical companies slaughter tens of thousands of Americans each year with impunity with deadly FDA-approved drugs.

See for yourself why clinical medical practice is advancing at a snail's pace, while the federal government goes to extraordinary lengths to stamp out those who seek natural and more innovative approaches to disease prevention and treatment.

The war against our health has penetrated government, academia, and the media to such a degree that no sound-bite explanation will expose the magnitude of the problem we face. But this film does!

So do yourself a huge favor. View War on Health* here and now… because you need to know. Then share it with your friends . . . because they do, too!

*Funded in part by an educational grant from the Life Extension Foundation®.

Latest Supplements 

Immune Modulator with Tinofend®,
60 vegetarian capsules

Item #01704

add to cart

The plant known as Tinospora cordifolia has a long tradition of use in Ayurvedic medicine. Tinofend® is a standardized extract of active compounds that work synergistically to provide immune-modulatory support. A double-blind, placebo-controlled clinical trial found that Tinofend® produced significant changes in several immune parameters that are known to help support healthy, immune system modulation.

Tinofend® promotes optimal immune health in three ways:

  • Helps support the activity that regulates immune response and enhances the function of protective cells called macrophages.
  • Helps limit the number of eosinophils (type of white blood cell) already within normal range.
  • Provides polysaccharides to help optimize the immune system's normal defenses, including neutrophil (type of white blood cell) function.

Immune Modulator with Tinofend® provides the versatile Tinospora compounds shown to help maintain the balanced cellular responsiveness, sensitivity and strength of an optimized and properly-modulated immune response.

Tinofend® is a registered trademark of Verdure Sciences, Inc.

Kyolic® Garlic Formula 102

ArthroMax™ with Theaflavins & AprèsFlex®, 120 vegetarian capsules
Item #01617
Featured Video

add to cart

As you grow older, age-related stiffness and discomfort in the joints becomes a fact of life. Activities once routine become a challenge as limited mobility hampers your every move. AprèsFlex® represents a quantum leap forward in the delivery to aging joints of boswellia, long prized for its ability to help with inflammatory issues. It is a superior inhibitor of the enzyme 5-lipoxygenase or 5-LOX.

Excess activity of 5-LOX results in the accumulation of leukotriene B4, a pro-inflammatory compound that affects aging joints. Boswellia has been shown to bind directly to the 5-LOX enzyme, preventing it from facilitating production of proinflammatory leukotrienes.

This ArthroMax™ with Theaflavins formulation provides bioactive theaflavin fractions, along with MSM (methylsulfonylmethane), which contains sulfur components that are critically important in maintaining comfortable joint function. It also contains FruiteX B® OsteoBoron®, a patented form of boron identical to natural plant forms found in food. Considered more bioavailable than other forms of boron, FruiteX B® OsteoBoron® supports healthy bones and joints.

AprèsFlex® is a registered trademark of Laila Nutraceuticals exclusively licensed to PLThomas – Laila Nutra LLC. International patents pending.

FruiteX B® and OsteoBoron® are registered trademarks of VDF FutureCeuticals, Inc. U.S. Patent No. 5,962,049.



Life Extension Update What's Hot
Melatonin, exercise show potential as Alzheimer's treatments Melatonin slows signs of aging in mice
Night light could equal weight gain Melatonin: high blood pressure remedy of the future?
Vitamin E and melatonin help prevent cognitive deficits in diabetic rats Melatonin may protect against Parkinson's disease
Life Extension Magazine® Health Topics
Beyond sleep: new medical applications for melatonin Diabetes
Beyond sleep: 7 ways melatonin attacks aging factors Insomnia
What is the proper dose of melatonin? Jet lag